2022 American Transplant Congress
First-in-human Study Of Lis1, A Novel Glyco-humanized Anti-lymphocyte Swine Polyclonal Antibody, In Kidney Transplantation: Safety And Efficacy
*Purpose: to assess safety, T cell depletion, PK/PD and determine the therapeutic dose of LIS1, a purified anti-lymphocyte glyco-humanized polyclonal swine IgG, derived by immunizing…2020 American Transplant Congress
Donor-Recipient Genetic Relationship and Outcomes of Living Donor Liver Transplantation (LDLT): Does it Really Matter?
1Henry Ford Hospital, Detroit, MI, 2University of Chicago Medical Center, Chicago, IL
*Purpose: The impact of donor-recipient genetic relationship on LDLT outcomes has been raised by some recent reports. We sought to study this over a large…2019 American Transplant Congress
Monitoring Inflammatory Cytokine Levels in Kidney Transplant Patients (KTx Pts) with Chronic Antibody Mediated Rejection (cABMR) Treated with Clazakizumab (CLZ, Humanized Anti-IL-6 Monoclonal Antibody)
*Purpose: IL-6 is a pro-inflammatory cytokine involved in KTx rejection. A clinical trial to improve cABMR using CLZ in HLA-sensitized KTx Pts is underway. Inhibition…2019 American Transplant Congress
Eculizumab in Kidney Transplant Recipients with Atypical Hemolytic Uremic Syndrome – Single Center Experience
Division of Transplant Nephrology, Johns Hopkins Hospital, Baltimore, MD
*Purpose: Atypical hemolytic uremic syndrome (aHUS) is caused by genetic mutations of components of the alternative complement pathway in 60-70% of cases; and has a…2019 American Transplant Congress
CD47 Blockade Promotes Hepatic Macrophage Polarization toward M1 during Normothermic Machine Perfusion of Discarded Human Livers
*Purpose: M1 macrophages have been shown to be able to phagocytize dead cells after ischemia-reperfusion injury (IRI). This study investigated the therapeutic effect of CD47…2019 American Transplant Congress
Systematic Testing and Specificity Mapping of Alloantigen-Specific Chimeric Antigen Receptors in T Regulatory Cells
University of British Columbia, Vancouver, BC, Canada
*Purpose: Achieving transplant tolerance with regulatory T cell (Treg) adoptive immunotherapy is currently under investigation as a therapy to reduce graft rejection and improve long-term…2017 American Transplant Congress
Multiple Dosing of Anti-C1s Antibody TNT009 – Effect on HLA Antibody-Triggered Complement Activation in Healthy Volunteers and Kidney Transplant Recipients with Antibody-Mediated Rejection.
Study purpose. Complement inhibition may be an attractive strategy to prevent antibody-mediated allograft injury. One promising therapeutic target may be the enzymatic activity of key…2017 American Transplant Congress
Safety and Activity of Anti-C1s Humanized Monoclonal Antibody TNT009 in Late Antibody-Mediated Kidney Allograft Rejection – Results of a First-in-Human Phase 1 Trial.
Study purpose:The classical pathway (CP) of complement may significantly contribute to antibody-mediated rejection (ABMR). Blockade of CP key component C1 may be a promising strategy…2017 American Transplant Congress
Eculizumab Dose Reduction Is Safe by Monitoring Eculizumab Pre-Dose Level and Functional Complement Assays.
Background & aims: Untreated atypical haemolytic syndrome (aHUS) leads to ESRD and may recur after renal transplantation. Eculizumab (Ecu), a humanized antibody inhibiting terminal C5…2016 American Transplant Congress
TNT009 and Its Parental Mouse Monoclonal Antibody TNT003 Target Complement Component C1s and Effectively Block Alloantibody-Induced Classical Complement Pathway Activation – The Preclinical Experience.
Introduction. Considering the key role of the classical complement pathway as a trigger of inflammation and injury in antibody-mediated rejection (ABMR), targeted classical pathway inhibition…
American Transplant Congress abstracts